Compare OVID & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OVID | QTRX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.5M | 306.0M |
| IPO Year | 2017 | 2017 |
| Metric | OVID | QTRX |
|---|---|---|
| Price | $2.83 | $3.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $4.60 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 4.6M | 925.7K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,252,000.00 | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | $22.53 | $9.82 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | 64.52 |
| 52 Week Low | $0.27 | $3.24 |
| 52 Week High | $3.11 | $8.77 |
| Indicator | OVID | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.19 | 36.36 |
| Support Level | $1.31 | $3.36 |
| Resistance Level | $3.11 | $3.90 |
| Average True Range (ATR) | 0.22 | 0.25 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 74.19 | 48.87 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.